Comparative Pharmacology
Head-to-head clinical analysis: BENZACLIN versus EVOCLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZACLIN versus EVOCLIN.
BENZACLIN vs EVOCLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZACLIN (clindamycin 1% and benzoyl peroxide 5%) is a combination antibacterial agent. Clindamycin is a lincosamide antibiotic that binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis and reducing Propionibacterium acnes growth. Benzoyl peroxide has bactericidal and keratolytic properties; it releases free radical oxygen species that oxidize bacterial proteins, decreasing P. acnes, and also causes drying and peeling of the skin.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Topical gel applied once or twice daily to affected areas. Each gram contains 1% clindamycin and 5% benzoyl peroxide.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
None Documented
None Documented
After topical application, plasma concentrations of clindamycin are negligible; the systemic half-life of clindamycin from absorbed fraction is approximately 2.5-3 hours in adults. However, due to minimal systemic absorption, the terminal half-life is not clinically relevant for topical therapy.
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
Benzaclin (clindamycin 1% - benzoyl peroxide 5%) is a topical formulation; systemic absorption is minimal. After topical application, less than 1% of clindamycin is absorbed. Absorbed clindamycin is primarily excreted in urine (10% as active drug, 90% as metabolites) and feces (<5%). Benzoyl peroxide is metabolized to benzoic acid, which is conjugated and excreted in urine. Overall, renal excretion accounts for the majority of clearance of absorbed components.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic